We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Sapience Therapeutics is a privately held company focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. Sapience identifies promising targets through a deep understanding of the transcriptional regulation of oncogenic or immune-modulatory proteins. Our targets may be non-traditional in drug discovery as they do not demonstrate enzymatic activities or act as ligand-binding receptors. Sapience has multiple approaches to generate initial hits, which are then optimized to therapeutic candidates based on decades of experience working with peptide and protein therapeutics. Sapience is looking to raise a series B financing in the first half of 2019.